Curcumin Analog E145 Suppresses NF-κB to Inhibit Breast Cancer Growth and Metastasis

Curcumin, the active compound in turmeric, has long been studied for its anti-inflammatory and anticancer properties. However, its poor bioavailability and chemical instability have limited its clinical utility. Researchers are now developing synthetic analogs that retain curcumin's benefits while overcoming these limitations.

A study published in Biological & Pharmaceutical Bulletin in 2026 investigated one such analog — E145, a monocarbonyl curcumin derivative — and found it potently suppresses breast cancer cell growth and metastasis through NF-κB inhibition.

Table of Contents

• What is E145 and how does it work?
• In vitro evidence: cell proliferation and NF-κB
• In vivo evidence: lung metastasis
• Limitations and future directions
• FAQ
• Shop Sanare Lab
• References

What is E145 and how does it work?

E145 is a synthetic monocarbonyl curcumin analog, specifically 3,5-bis(2'-ethoxybenzylidene)-piperidine-4-one. Unlike natural curcumin, which degrades rapidly in the body, E145 is designed to be more chemically stable while preserving the biological activity of the parent compound. The study tested E145 in two breast cancer models: murine 4T1 cells and human MDA-MB-231 triple-negative breast cancer cells.

The mechanism centers on NF-κB (nuclear factor-kappaB), a protein complex that acts as a master regulator of inflammation, cell survival, and proliferation. When activated, NF-κB enters the nucleus and switches on genes that promote tumor growth, angiogenesis (the formation of new blood vessels), and metastasis. E145 was found to suppress phosphorylation of the NF-κB p65 subunit and block its nuclear translocation, effectively shutting down this pro-tumorigenic signaling cascade.

In vitro evidence: cell proliferation and NF-κB

In cell culture experiments, E145 inhibited the proliferation of both 4T1 and MDA-MB-231 breast cancer cells in a dose-dependent manner. Western blotting confirmed that E145 reduced phosphorylation of NF-κB p65 and prevented its entry into the nucleus.

Consistent with NF-κB suppression, E145 also downregulated several NF-κB-driven genes linked to cancer progression: vascular endothelial growth factor (VEGF), which promotes blood vessel formation; matrix metalloproteinase-9 (MMP-9), which breaks down tissue barriers to allow invasion; and the inflammatory cytokines interleukin-1β (IL-1β) and interleukin-6 (IL-6).

In vivo evidence: lung metastasis

To test whether the in vitro findings translate to a living organism, the researchers used an experimental lung metastasis model in mice. Breast cancer cells were injected intravenously, and animals were treated with E145. The results showed that E145 significantly reduced the number of metastatic tumor colonies in the lungs compared to untreated controls, confirming its antimetastatic potential in vivo.

For context on how natural curcumin itself performs, see our review of what the human and preclinical curcumin research actually shows.

Limitations and future directions

This study is entirely preclinical. All experiments were conducted in cell lines and mice, not in human patients. There are no clinical trials of E145 in breast cancer, and the compound is not available as a commercial supplement or drug. Natural curcumin supplements differ significantly from E145 in structure, stability, and potency, so these results should not be extrapolated to over-the-counter turmeric products.

For readers exploring curcumin dosing, our protocol dosing calculator can map out a weight-based schedule.

Frequently Asked Questions

Shop Sanare Lab

Lab-tested products referenced in the research above. Links are provided for convenience — always review the label and consult a professional before use.

Disclaimer: Links are informational and for convenience. This site does not provide medical advice and does not endorse any specific vendor. Always verify product quality, labeling, and consult a licensed professional for health decisions.

References

1. Jabbar S, Zhou Y, Kobayashi S, He K, Ucche S. A Curcumin Analog, 3,5-Bis(2'-ethoxybenzylidene)-piperidine-4-one (E145), Suppresses NF-κB Signaling to Inhibit Breast Cancer Growth and Metastasis. Biol Pharm Bull. 2026; DOI: 10.1248/bpb.b26-00307. PMID: 42528202.

Medical Disclaimer

This article is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before making any health decisions. The research discussed is preclinical and has not been evaluated in human clinical trials.